Physician profile
Saji Abraham
NPI 1497955603
$3,038.87
in general payments reported to CMS, 2019-2025
21 companies · $684 in 2025
The $684 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $61.74 · 2021: $300 · 2022: $322 · 2023: $601 · 2024: $681 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,773 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,772.82 |
| Education | $193.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $412.80 | 2022-2025 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $318.71 | 2024-2025 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $287.79 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $281.35 | 2021-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $213.31 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.88 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $195.14 | 2022-2025 | Wainua, Farxiga |
| Boston Scientific Corporation | $170.99 | 2019-2024 | Watchman Flx |
| Pfizer INC. | $167.64 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $164.52 | 2020-2025 | Eliquis, Camzyos |
| Aurinia Pharma U.S., INC. | $125.00 | 2025 | Lupkynis |
| Vifor Pharma, INC. | $124.73 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $122.62 | 2022 | |
| Opko Pharmaceuticals, LLC | $95.25 | 2024-2025 | Rayaldee |
| Lilly USA, LLC | $27.05 | 2025 | Zepbound, Mounjaro |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $24.07 | 2019 | |
| Almatica Pharma LLC | $22.83 | 2025 | Loreev Xr |
| Amarin Pharma, INC. | $22.70 | 2019 | |
| Mallinckrodt Hospital Products INC. | $21.87 | 2025 | Acthar |
| Bridgebio Pharma, INC. | $20.95 | 2025 | Attruby |
| Preventice Services, LLC | $14.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saji Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.